Actively Recruiting
Study of AI-Powered Retinal Imaging and Blood Tests to Detect Alzheimers-Related Protein Changes in Adults with Mild Cognitive Issues
Led by Eli Lilly and Company · Updated on 2026-09-24
200
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a screening tool that uses retinal imaging to detect changes in the eye related to Alzheimers disease in adults with memory problems. The study focuses on individuals with mild memory complaints or mild cognitive impairment and aims to compare retinal scan results with blood tests to detect abnormal protein deposits associated with Alzheimers disease. Participants will undergo a retinal scan and blood test during a single visit. The retinal scan provides detailed images of the retina, while the blood test checks for a specific protein linked to early Alzheimers detection. This observational study lasts up to one month for each participant and involves no drug treatments. During the study visit, participants will have their retina scanned and blood drawn for testing. Researchers will measure how often the retinal scan and blood test results agree and will assess participant satisfaction with the retinal scan. The study is sponsored by Eli Lilly and Company and includes adults aged 55 and older with mild cognitive issues. Participants are monitored only during the one study visit, and no long-term treatment or follow-up is required.
CONDITIONS
Brief Title
A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here